- Home
- DXR vs TPST Comparison
DXR vs TPST Comparison
Compare DXR & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXR
- TPST
- Stock Information
- Founded
- DXR 1970
- TPST 2011
- Country
- DXR United States
- TPST United States
- Employees
- DXR N/A
- TPST N/A
- Industry
- DXR Medical/Dental Instruments
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- DXR Health Care
- TPST Health Care
- Exchange
- DXR Nasdaq
- TPST Nasdaq
- Market Cap
- DXR 36.4M
- TPST 33.0M
- IPO Year
- DXR N/A
- TPST N/A
- Fundamental
- Price
- DXR $9.75
- TPST $6.86
- Analyst Decision
- DXR Strong Buy
- TPST Hold
- Analyst Count
- DXR 1
- TPST 3
- Target Price
- DXR $25.00
- TPST $30.00
- AVG Volume (30 Days)
- DXR 5.6K
- TPST 247.2K
- Earning Date
- DXR 01-01-0001
- TPST 08-07-2025
- Dividend Yield
- DXR N/A
- TPST N/A
- EPS Growth
- DXR 86.16
- TPST N/A
- EPS
- DXR 0.11
- TPST N/A
- Revenue
- DXR $119,714.00
- TPST N/A
- Revenue This Year
- DXR N/A
- TPST N/A
- Revenue Next Year
- DXR N/A
- TPST N/A
- P/E Ratio
- DXR $84.18
- TPST N/A
- Revenue Growth
- DXR N/A
- TPST N/A
- 52 Week Low
- DXR $6.55
- TPST $5.35
- 52 Week High
- DXR $10.00
- TPST $30.03
- Technical
- Relative Strength Index (RSI)
- DXR 69.88
- TPST 49.91
- Support Level
- DXR $8.68
- TPST $6.87
- Resistance Level
- DXR $9.03
- TPST $7.25
- Average True Range (ATR)
- DXR 0.47
- TPST 0.67
- MACD
- DXR 0.03
- TPST -0.02
- Stochastic Oscillator
- DXR 90.38
- TPST 11.20
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.